DOCSLIB.ORG

Test Update Notification, Effective December 7, 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Test Update Notification, Effective December 7, 2015 Effective Date: Monday, December 07, 2015 Test Updates In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, December 07, 2015 Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Discontinued Tests - Tests being discontinued with alternate testing suggestions. Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases. If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes. The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document. NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 1 of 15 Effective Date: Monday, December 07, 2015 Test Updates Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments Antidepressants / Antihistamines 52467U • Confirmation Panel 1, Urine (Forensic) 1330N Copper, Nails • 2915U Dextro / Levo Methorphan - Total, Urine • • • • • Dextro / Levo Methorphan Screen - Total, 9205U • • • • • Urine Dextro/Levo Methorphan Confirmation - 5495U • • • • • Total, Urine Dextromethorphan and Metabolite Ratio - 2917U • • • • • Total, Urine Dextrorphan / Levorphanol Confirmation - Total (Qualitative) (Drug Impaired 54349U • • • • • Driving/DRE Toxicology), Urine (Forensic) Dextrorphan / Levorphanol Confirmation - 55016U • • • • • Total, Urine (CSA) Dextrorphan / Levorphanol Confirmation - 52061U • • • • • Total, Urine (Forensic) Dextrorphan / Levorphanol Confirmation, 5117SP • Serum/Plasma Dextrorphan / Levorphanol Confirmation, 52061SP • Serum/Plasma (Forensic) Dextrorphan / Levorphanol Screen, 2506SP • Serum/Plasma 1789B Diquat, Blood • 1789SP Diquat, Serum/Plasma • GC Confirmation Set 1 (Qualitative) 54337U (Drug Impaired Driving/DRE Toxicology), • Urine (Forensic) 52410U GC Confirmation Set 1, Urine (Forensic) • 5527SP Haloperidol Confirmation, Serum/Plasma • Haloperidol Confirmation, Serum/Plasma 52053SP • (Forensic) 9182SP Haloperidol Screen, Serum/Plasma • 2220SP Haloperidol, Serum/Plasma • 5553SP Meclizine Confirmation, Serum/Plasma • Meclizine Confirmation, Serum/Plasma 52066SP • (Forensic) 9196SP Meclizine Screen, Serum/Plasma • 2590SP Meclizine, Serum/Plasma • Methadone Confirmation (Drug Impaired 55060U Driving/DRE Toxicology), Urine • (Forensic) (CSA) IN/LA Methadone and Metabolite (Drug 10038SP Impaired Driving-DRE Toxicology), • Serum/Plasma (Forensic) (CSA) NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 2 of 15 Effective Date: Monday, December 07, 2015 Test Updates Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments Methadone and Metabolite Confirmation 55047U (Drug Impaired Driving/DRE Toxicology), • Urine (Forensic) (CSA) IN/LA Methadone and Metabolite Confirmation 54005U (Qualitative) (Drug Impaired Driving/DRE • Toxicology), Urine (Forensic) Methadone and Metabolite Confirmation 52257U • (Qualitative), Urine (CSA) Methadone and Metabolite Confirmation, 5682SP • Serum/Plasma Methadone and Metabolite Confirmation, 50015SP • Serum/Plasma (Forensic) Methadone and Metabolite Confirmation, 5682U • Urine Methadone and Metabolite Confirmation, 50015U • Urine (Forensic) Methadone and Metabolite, 8722SP • Serum/Plasma 8722U Methadone and Metabolite, Urine • 90006U Opioids Screen, Urine (CSA) • • • 3325B Paraquat, Blood • 3325SP Paraquat, Serum/Plasma • Paroxetine Confirmation, Serum/Plasma 52096SP • (Forensic) 3360SP Paroxetine, Serum/Plasma • Phencyclidine Confirmation (Qualitative), 52259U • Urine (CSA) 5657U Phencyclidine Confirmation, Urine • Phencyclidine Confirmation, Urine 50017U • (Forensic) Phencyclidine Confirmation, Urine 52464U • (Forensic) 3532U Phencyclidine Screen, Urine • 8761U Phencyclidine, Urine • 3776SP Pimozide, Serum/Plasma • Sertraline and Desmethylsertraline 52116SP • Confirmation, Serum/Plasma (Forensic) Sertraline and Desmethylsertraline, 4195SP • Serum/Plasma Synthetic Cannabinoids Confirmation, 5960B • Blood (Forensic) NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 3 of 15 Effective Date: Monday, December 07, 2015 Test Updates Test Changes 52467U Antidepressants / Antihistamines Confirmation Panel 1, Urine (Forensic) Summary of Changes: Scope of Analysis was changed. Dextro / Levo Methorphan was removed. Scope of Analysis: GC (80332, 80335, 80338, 80376, 80362, 80376): Amitriptyline, Nortriptyline, Method (CPT Code) Doxepin, Desmethyldoxepin, Doxylamine, Fluoxetine, Norfluoxetine, Trazodone, Mirtazapine, Verapamil 2915U Dextro / Levo Methorphan - Total, Urine Summary of Changes: Test Name was changed. Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Methods/CPT Codes were changed [LC-MS/MS (80362)] Dextro / Levo Methorphan was renamed to Dextro / Levo Methorphan - Total. Specimen Requirements: 1 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s) Scope of Analysis: LC-MS/MS (80362): Dextro / Levo Methorphan - Total Method (CPT Code) 9205U Dextro / Levo Methorphan Screen - Total, Urine Summary of Changes: Test Name was changed. Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Methods/CPT Codes were changed [LC-MS/MS (80302)] Dextro / Levo Methorphan was renamed to Dextro / Levo Methorphan - Total Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 4 of 15 Effective Date: Monday, December 07, 2015 Test Updates Test Changes Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s) Scope of Analysis: LC-MS/MS (80302): Dextro / Levo Methorphan - Total Method (CPT Code) 5495U Dextro/Levo Methorphan Confirmation - Total, Urine Summary of Changes: Test Name was changed. Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Methods/CPT Codes were changed [LC-MS/MS (80362)] Dextro / Levo Methorphan was renamed to Dextro / Levo Methorphan - Total Specimen Requirements: 1 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s) Scope of Analysis: LC-MS/MS (80362): Dextro / Levo Methorphan - Total Method (CPT Code) 2917U Dextromethorphan and Metabolite Ratio - Total, Urine Summary of Changes: Test Name was changed. Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed. Methods/CPT Codes were changed [LC-MS/MS (80362)] Dextromethorphan was rename to Dextromethorphan - Total. Dextrorphan was rename to Dextrorphan - Total. Specimen Requirements: 1 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 5 of 15 Effective Date: Monday, December 07, 2015 Test Updates Test Changes Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s) Scope of Analysis: LC-MS/MS (80362): Dextrorphan - Total, Dextromethorphan - Total, Metabolic Ratio Method (CPT Code) 54349U Dextrorphan / Levorphanol Confirmation - Total (Qualitative) (Drug Impaired Driving/DRE Toxicology), Urine (Forensic) Summary of Changes: Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Scope of Analysis was changed. Methods/CPT Codes were changed [LC-MS/MS (80362)] Dextrorphan / Levorphanol was renamed to Dextrorphan / Levorphanol - Total Specimen Requirements: 1 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (preservative-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s) Scope of Analysis: LC-MS/MS (80362): Dextrorphan / Levorphanol - Total Method (CPT Code) 55016U Dextrorphan / Levorphanol Confirmation - Total, Urine (CSA) Summary of Changes: Test Name was changed. Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Dextrorphan / Levorphanol - Total was added. Methods/CPT Codes were changed [LC-MS/MS (80362)] Levorphanol was removed. Specimen Requirements: 1 mL Urine Transport Temperature: Refrigerated Specimen Container:
Load more

Recommended publications
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • Proposal for Reclassification of Cough Medicines Containing Dextromethorphan, Opium Tincture, Squill Oxymel and Pholcodine to Restricted Medicines
    Proposal for reclassification of cough medicines containing dextromethorphan, opium tincture, squill oxymel and pholcodine to restricted medicines Purpose Medsafe has recently been alerted to instances of abuse of cough medicines containing dextromethorphan. Concern was raised over the easy availability of opioid (and opioid-like) cough medicines which can be bought at a pharmacy or supermarket without healthcare professional supervision. Dextromethorphan is a substance that does not belong to the opioid family but has a chemical structure closely resembling the opioids. Dextromethorphan has a history of abuse in New Zealand and other countries. There are also other cough medicines available as pharmacy medicines which have been noted as at least having a potential for abuse, for example cough medicines containing pholcodine and Gees linctus which contains anhydrous morphine. Pholcodine and anhydrous morphine are both opioids. Medsafe therefore requests that Medicines Classification Committee (MCC) considers reclassification of dextromethorphan, opium tincture, squill oxymel and pholcodine containing products to Pharmacist-Only (restricted) medicines. Medsafe considers that a reclassification to restricted medicine balances a need for better supervision whilst maintaining access for those who benefit from using these medicines. Background Dextromethorphan and misuse (1) Dextromethorphan (DXM) is the D- isomer of the codeine synthetic analogue, levorphanol. DXM also structurally resembles ketamine and phenycycline which are dissociative agents, meaning that they can be used to incite a type of general anesthesia characterized by analgesia and amnesia with minimal effect on respiratory function. DXM is an opioid, but because of its stereochemistry, DXM and its metabolites do not bind to the mu and delta opioid receptors, thus avoiding classic opioid toxicity.
    [Show full text]
  • University of Groningen Stereoselectivity in the Hepatic Metabolism and Transport of Quaternary Drugs of the Morphinan Type Lant
    University of Groningen Stereoselectivity in the hepatic metabolism and transport of quaternary drugs of the morphinan type Lanting, Aleida Bartha Louisa IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2000 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Lanting, A. B. L. (2000). Stereoselectivity in the hepatic metabolism and transport of quaternary drugs of the morphinan type. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 24-09-2021 In this thesisthe potential of some quaternaryamine derivativesof the morphinan analoguesdextrorphan, levorphanol, dextromethorphan and levomethorphanas model compoundswas investigatedto study stereoselectivityin hepatic metabolismand transport of cationic drugs.These model compoundspossess a rigid stereochemicalstructure, resulting in major differencesin receptor affinity. We assumedthat the major influenceof the stereochemicalstructure on the receptor level might also causedifferences in carrier-mediatedtransport and biotransformation processes.
    [Show full text]
  • Urine Drug Toxicology and Pain Management Testing
    Urine Drug Toxicology and Pain Management Testing Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA Learning Objectives • Describe what chronic pain is, who is affected and how they are commonly treated • Explain the common methodologies used in pain management testing • Interpret urine drug testing results • Create protocols to minimize the occurrence of false positive or false negative results Pain – definition and types • Pain - an unpleasant sensory and emotional experience associated with actual or potential tissue damage • Chronic pain - pain that extends beyond the expected period of healing • Nociceptive Pain – Pain caused by tissue injury – Stimulus-evoked, high intensity – Opioid sensitive • Neuropathic Pain – Caused by nerve injury – Spontaneous activity – Develops in days or month – Opioid insensitive Chronic Pain Patients • Arthritis • Fibromyalgia – Osteoarthritis • Headaches – Rheumatoid arthritis – Migraine – Gout – Tension • Cancer – Cluster • Chronic non-cancer pain • Myofascial pain • Central pain syndrome • Neuropathic pain – CNS damage – Diabetic Peripheral – Multiple Sclerosis Neuropathy – Parkinson’s disease – Postherpetic neuralgia • Chronic abnominal pain • Neck and Back Pain – Intestinal obstructions Chronic Pain Medications • Opiates • Synthetic opioids – Codeine – Fentanyl – Morphine – Methadone • Semi-synthetic opioids – Meperidine – Oxymorphone – Tramadol – Oxycodone – Propoxyphene – Hydromorphone – Levorphanol – Hydrocodone – Tapentadol – Buprenorphine • Anticonvulsant • Muscle
    [Show full text]
  • Dextrorphan Binds to Opioid Receptors in Guinea-Pig Brain Membranes And
    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 1629-1632, March 1990 Pharmacology Dextrorphan binds to opioid receptors in guinea-pig brain membranes and is an antagonist at opioid receptors in myenteric plexus (binding/guinea-pig ileum/levorphanol/stereoselectivity) AVRAM GOLDSTEIN AND ASHA NAIDU Department of Pharmacology, Stanford University, Stanford, CA 94305 Contributed by Avram Goldstein, December 11, 1989 ABSTRACT Dextrorphan (+)-tartrate, purified by re- LaRoche); [D-Ala,MePhe4,Gly-ol5]enkephalin (DAGO; Pe- peated crystallization to remove all traces of the enantiomer ninsula Laboratories) (2); trans-3,4-dichloro-N-methyl- levorphanol, binds to IL, 6, and K sites on guinea-pig brain N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide methane- membranes with lower affinities (by a factor of400-3200) than sulfonate (U50,488; Upjohn) (3); (-)-naloxone hydrochloride levorphanol. In the guinea-pig ileum myenteric plexus longi- (NAL; Endo Laboratories, New York); normorphine hydro- tudinal muscle preparation (GPI), dextrorphan, at 100-200 chloride (NOR) and (+)-naloxone hydrochloride (National ,uM, inhibits the electrically stimulated twitch, but this action Institute on Drug Abuse); N-methyl-D-aspartic acid (NMDA), is not blocked or reversed by naloxone; both (+)- and (-)- aminophosphonovalerate, norepinephrine (levarterenol), at- naloxone produce similar non-opioid twitch inhibition at com- ropine, and eserine (physostigmine) (Sigma). parable concentrations. At 10-20 jaM, dextrorphan' blocks and Preparation ofDEXp. [3H]LEV (Ro 1-5431/701, Hoffmann- reverses the twitch inhibition due to ,u and KWagonists, but the LaRoche; 17.4 Ci/mmol; 1 Ci = 37 GBq) was purified' by blockade can be overcome only partially by increasing the preparative reversed-phase HPLC (Waters, C18 AgBondaPak, agonist concentration.
    [Show full text]
  • Dextromethorphan and Memantine After Ketamine Analgesia: a Randomized Control Trial
    Drug Design, Development and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Dextromethorphan and memantine after ketamine analgesia: a randomized control trial This article was published in the following Dove Press journal: Drug Design, Development and Therapy Elodie Martin,1 Marc Sorel,2 Purpose: Intravenous ketamine is often prescribed in severe neuropathic pain. Oral N- 3 Véronique Morel, Fabienne methyl-D-aspartate receptor (NMDAR) antagonists might prolong pain relief, reducing the 4 4 Marcaillou, Pascale Picard, frequency of ketamine infusions and hospital admissions. This clinical trial aimed at asses- Noémie Delage,4 Florence sing whether oral dextromethorphan or memantine might prolong pain relief after intrave- Tiberghien,5 Marie-Christine 6 6 nous ketamine. Crosmary, Mitra Najjar, Renato Colamarino,6 Christelle Créach,7,8 Patients and methods: A multicenter randomized controlled clinical trial included 60 Béatrice Lietar,7 Géraldine Brumauld patients after ketamine infusion for refractory neuropathic pain. Dextromethorphan (90 mg/ de Montgazon,9 Anne Margot- day), memantine (20 mg/day) or placebo was given for 12 weeks (n=20 each) after ketamine 10 11,12 Duclot, Marie-Anne Loriot, infusion. The primary endpoint was pain intensity at one month. Secondary endpoints 11,12 13 Céline Narjoz, Céline Lambert, included pain, sleep, anxiety, depression, cognitive function and quality of life evaluations 13 1,3 Bruno Pereira, Gisèle Pickering up to 12 weeks. 1Université Clermont Auvergne, Pharmacologie Results: At 1 month, dextromethorphan maintained ketamine pain relief (Numeric Pain Fondamentale Et Clinique de la Douleur, Neuro- Dol, Inserm 1107, F-63000 Clermont-Ferrand, Scale: 4.01±1.87 to 4.05±2.61, p=0.53) and diminished pain paroxysms (p=0.03) while pain France; 2Centre D’evaluation et de Traitement de intensity increased significantly with memantine and placebo (p=0.04).
    [Show full text]
  • Neurolept Anaesthesia: a Comparison with a Conventional Technique for Major Surgery*
    NEUROLEPT ANAESTHESIA: A COMPARISON WITH A CONVENTIONAL TECHNIQUE FOR MAJOR SURGERY* S. A. McDOWELL,M.B., F./~.A.I~.C.S. AND J. W. DUNDEE, 1VI.D.,PH.D., F.F.A.H.C.S. IN THE PAST DECADE, the term "neuroleptic" has been increasingly used to describe the effects of certain drugs on the central nervous system. It is usually used to signify the production of tranquillity and mental detachment, without a marked soporific effect. If a narcotic analgesic is used in combination with a neuroleptic drug, then a state of neurolept-analgesia is produced and if, in this state, a hypnotic is added to produce sleep, the result is neurolept anaesthesia (NLA). Since the introduction of this form of anaesthesia by De Castro and Mundeleer 1 a great variety of techniques of NLA have been described and many claims made for its advantages over more conventional forms of anaesthesia. 2-6 Among these are: (a) stability of the cardiovascular system, making it particularly suited for the poor-risk patient. (b) profound analgesia, which extends into the postoperative period and results in comfort for the patient and ease of management. (e) little postoperative nausea and vomiting. (d) rapid recovery of consciousness with good tolerance of endotraeheal tubes and patient cooperation. In spite of these advantages, neuroleptanaesthesia has not found acceptance with all workers 7 and recently, the usefulness of the drugs used in NLA has been ques- tioned by workers from this department, s,9 The neuroleptic drug commonly used in this form of anaesthesia is droperidol and it is usually given in conjunction with the analgesic fentanyl.
    [Show full text]
  • Levorphanol Use: Past, Present and Future
    Postgraduate Medicine ISSN: 0032-5481 (Print) 1941-9260 (Online) Journal homepage: http://www.tandfonline.com/loi/ipgm20 Levorphanol Use: Past, Present and Future Jeffrey Gudin, Jeffrey Fudin & Srinivas Nalamachu To cite this article: Jeffrey Gudin, Jeffrey Fudin & Srinivas Nalamachu (2015): Levorphanol Use: Past, Present and Future, Postgraduate Medicine, DOI: 10.1080/00325481.2016.1128308 To link to this article: http://dx.doi.org/10.1080/00325481.2016.1128308 Accepted author version posted online: 03 Dec 2015. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ipgm20 Download by: [Jeffrey Fudin] Date: 03 December 2015, At: 20:32 Publisher: Taylor & Francis Journal: Postgraduate Medicine DOI: 10.1080/00325481.2016.1128308 Levorphanol Use: Past, Present and Future Authors: Jeffrey Gudin1, Jeffrey Fudin2, and Srinivas Nalamachu3 Affiliations: 1Director, Pain Management and Palliative Care, Englewood Hospital and Medical Center, Englewood, NJ, and Clinical Instructor, Anesthesiology, Icahn School of Medicine at Mount Sinai, New York, NY. 2Adjunct Associate Professor, Albany College of Pharmacy and Health Sciences and also Western New England University College of Pharmacy Director, PGY2 Pain Residency and Clinical Pharmacy, Specialist, Pain Management Stratton VA Medical Center, Albany, NY 3President and Medical Director, International Clinical Research Institute, Overland Park, KS, and Adjunct Associate Professor, Temple University School of Medicine, Downloaded by [Jeffrey Fudin] at 20:32 03 December 2015 Philadelphia, PA. Running Title: Levorphanol Use: Past, Present and Future Corresponding Author Srinivas Nalamachu Srinivas R. Nalamachu MD International Clinical Research Institute, Inc.
    [Show full text]
  • Chronic Pain Levorphanol Methadone and the N Methyl D Aspartate
    JPM-2009-0105-Letter to the Editor_1P.3d 07/21/09 2:53pm Page 1 JPM-2009-0105-Letter to the Editor_1P JOURNAL OF PALLIATIVE MEDICINE Volume 12, Number 9, 2009 Letter to the Editor ª Mary Ann Liebert, Inc. DOI: 10.1089=jpm.2009.0105 Chronic Pain: Levorphanol, Methadone, and the N-Methyl-d-Aspartate Receptor Dear Editor: patients, whose pain score was reduced to a score of 4 to 5. The Not every clinician is in a position to undertake controlled overall response rate to treatment with methadone ap- trials to advance the science and practice of medicine. Even proached 75%. The pain relief provided by levorphanol was researchers in academic institutions are subject to problems quite similar to that from methadone. Of the 73 patients who with funding the cost of studies. End-of-life care, which is received levorphanol, 35 had an excellent response and 14 increasingly provided in the home, is beset with ethical and experienced fair relief. The overall response rate to levor- logistical problems regarding the use of evidence-based prin- phanol was 70%. ciples to study patients. Physicians practicing in home hos- Levorphanol is a m- and k-receptor agonist and an NMDA pice settings are in a much different environment than those receptor antagonist. With respect to effectiveness and adverse- who work in hospitals and teaching institutions, and studies effect profile, it is much like hydromorphone but offers these in those locations may not be comparable. important advantages: Levorphanol relieves neuropathic If a concept, new or old, is attractive to a physician because pain, and 1 dose is effective for 6, 8, or 12 hours as opposed to it may improve the care of patients and if a controlled trial is the 3 to 4 hours of relief afforded by hydromorphone.
    [Show full text]
  • ICE 2020/1 Seized Materials Test Group
    INTERNATIONAL COLLABORATIVE EXERCISES (ICE) Summary Report ICE Round 2020/1 1 SEIZED MATERIALS / 20 ICE 20 International Collaborative Exercises (ICE) Summary report 2020/1-Seized Materials Final summary report for ICE 2020/1 Seized Materials Test Group Original language: English © United Nations, January 2021. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. ICE 2020/1-SM Copyright © 2021 UNODC Page 1 of 104 International Collaborative Exercises (ICE) Summary report 2020/1-Seized Materials Acknowledgements The Laboratory and Scientific Section (LSS) of the UNODC, headed by Dr. Justice Tettey, wishes to express its appreciation and thanks to all laboratories for participating in the International Collaborative Exercises (ICE) round 2020/1. The valuable comments and contribution from the following members of the International Panel of Forensic Experts are gratefully acknowledged: Mr. Benoit Archambault, Health Canada, Canada Mr. Elvio Dias Botelho, Brazilian Federal Police, Brazil Prof. Heesun Chung, Sungkyunkwan University, Republic of Korea Prof. Niamh Nic Daéid, University of Dundee, Scotland, UK Mr. Scott Oulton, Drug Enforcement Administration, USA Ms. Catherine Quinn, Victoria Police, Australia Prof. Franco Tagliaro, University of Verona, Italy Dr. Angeline Tiong Whei Yap, Health Sciences Authority, Singapore In addition, LSS would like to acknowledge the valuable contribution of the Chemical Metrology Laboratory of the Health Sciences Authority, Singapore, for the provision of specific software used for the quantitative statistical calculations in the ICE programme.
    [Show full text]